Holen Sie sich die Stockscreener-App
3.66
0.81%
-0.03
Handel nachbörslich:
3.66
Ironwood Pharmaceuticals Inc Aktie (IRWD) Neueste Nachrichten
Ironwood Pharmaceuticals (IRWD) Jefferies London Healthcare Conference 2024 Summary - Quartr
Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026 - TradingView
Ironwood Pharmaceuticals (IRWD) retires $200M 2026 convertible notes in cash - Stock Titan
Ironwood Pharmaceuticals (IRWD) Beats Q2 Earnings and Revenue Estimates - MSN
Ironwood Pharmaceuticals (IRWD) Tops Healthcare Sector with Stro - GuruFocus
These healthcare stocks are combining strong gains with reasonable prices (XLV:NYSEARCA) - Seeking Alpha
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026? - Yahoo Finance
· SEC Filing - MLQ.ai
IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Chart - ChartMill
IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead - TradingView
Ironwood Pharmaceuticals Signals Blockbuster Momentum in 2026 - The Globe and Mail
Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price, News, Quote & History - Yahoo Finance
Ironwood Pharmaceuticals Expands Linzess Use and Drives Record Q1 2026 Revenue - asatunews.co.id
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess? - Insider Monkey
Ironwood (IRWD) Q1 2026 Earnings Call Transcript - The Globe and Mail
Earnings Preview: IRWD to Report Financial Results Pre-market on May 07 - Moomoo
Ironwood reiterates 2026 LINZESS guidance of $1.125B-$1.175B as STARS-2 initiation nears - MSN
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2026 - BioSpace
Ironwood Pharmaceuticals to Present at Jefferies Global Healthcare Conference - geneonline.com
Ironwood Pharmaceuticals, Inc. (IRWD) stock price, news, quote and history - Yahoo Finance UK
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference - investor.ironwoodpharma.com
Ironwood Pharmaceuticals (IRWD) Gains FDA Approval for Linzess i - GuruFocus
FDA approves Linzess for children ages 2-5 with constipation - Investing.com UK
Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation - Seeking Alpha
FDA approves constipation drug LINZESS for kids as young as 2 - Stock Titan
Ironwood Pharmaceuticals (IRWD) Receives Strong Buy Rating Follo - GuruFocus
Ironwood Pharmaceuticals (IRWD) Earns Strong Buy Rating from Qua - GuruFocus
Ironwood Pharmaceuticals: A Contrarian Buy Opportunity (NASDAQ:IRWD) - Seeking Alpha
Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant - Stock Titan
Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant - Stock Titan
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement? - Insider Monkey
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Top Small-Cap Stocks to Watch: Ironwood Pharmaceuticals (IRWD) L - GuruFocus
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer - GlobeNewswire
Ironwood Pharma drops after CFO transition - MSN
Ironwood Pharmaceuticals: Still A Profitable Opportunity (NASDAQ:IRWD) - Seeking Alpha
Armistice reports 15.03M Ironwood stake (NASDAQ: IRWD) in 13G/A - Stock Titan
Ironwood Pharmaceuticals, Inc.Class A Common Stock (NQ: IRWD - FinancialContent
Renaissance reports 4.90% stake in Ironwood (IRWD) - Stock Titan
Craig-Hallum Maintains Ironwood Pharmaceuticals(IRWD.US) With Buy Rating - Moomoo
Ironwood Pharma Announces CFO Resignation and Interim Successor - The Globe and Mail
2.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):